EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online October 10, 2008
Experimental Biology and Medicine 233:1482-1483 (2008)
doi: 10.3181/0806-S-208
© 2008 by the Society for Experimental Biology and Medicine
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
233/12/1482    most recent
0806-S-208v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Blake, C. A.
Right arrow Articles by Sobel, B. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blake, C. A.
Right arrow Articles by Sobel, B. E.

SYMPOSIUM: PROGRESS IN PHARMACOGENETICS AND ITS PROMISE FOR MEDICINE

Progress in Pharmacogenomics and Its Promise for Medicine

Charles A. Blake*,1 and Burton E. Sobel{dagger}

* Department of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, South Carolina 29208; and {dagger} the Cardiovascular Research Institute, University of Vermont, Colchester Research Facility, Colchester, Vermont 05446

To whom requests for reprints should be addressed at 1 Department of Cell Biology and Anatomy, University of South Carolina, School of Medicine, 6439 Garners Ferry Rd., Columbia, SC 29208. E-mail: blake{at}med.sc.edu

Abstract

Pharmacogenomics addresses the impacts of diverse and multiple genes in populations as determinants of responses of individual patients to drugs. The field has its roots in basic science, and is pivotal in drug development, elucidation of therapeutic efficacy, and constraining the risks of adverse drug reactions. Regulatory agencies are relying increasingly on pharmacogenomics for identification of patients who are particularly likely to benefit from treatment with specific agents and exclusion of those at risk of adverse drug reactions. Practical applications of pharmacogenomics already abound particularly in the use of drugs acting on the central nervous system and on the cardiovascular system. The Society for Experimental Biology and Medicine (SEBM) is proud and pleased to have devoted its 2008 symposium, presented at the annual Experimental Biology meeting in San Diego on April 6, 2008, to advances in pharmacogenomics with emphasis on drug development, regulatory agency considerations, and clinical applications.

Key Words: pharmacogenetics • pharmacogenomics • single gene polymorphisms






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Experimental Biology and Medicine.